Axsome Therapeutics Inc

Machine Learning Scientist II/Sr (Omics) - UK

Roorkee, Uttarakhand, India

Not SpecifiedCompensation
Junior (1 to 2 years)Experience Level
Full TimeJob Type
UnknownVisa
Biotechnology, Pharmaceuticals, Computational BiologyIndustries

Machine Learning Scientist, Omics Integration

Employment Type: Full-Time Location Type: Remote Salary: [Not Specified]

Position Overview

Iambic Therapeutics is seeking a Machine Learning Scientist to enhance our multimodal transformer, Enchant, by integrating omics signals such as genomics, transcriptomics, proteomics, and metabolomics. This role will primarily focus on target selection and biomarker discovery. The successful candidate will be responsible for creating robust data pipelines, curating benchmarking datasets, and developing models that combine multi-omics information with existing context in Enchant. A strong understanding of causal experimental design and the interactions among diverse molecular modalities is crucial. While the position is remote, candidates located in Bristol are preferred.

Key Responsibilities

  • Data Acquisition & Management:
    • Identify, prioritize, and acquire multi-omics datasets.
    • Build, maintain, and document data pipelines for ingesting, quality-controlling, and harmonizing large multi-omics datasets from public and proprietary sources.
  • Model Development & Application:
    • Design schemes for pretraining and finetuning Enchant on multi-omics data.
    • Define benchmarks for target-selection and biomarker tasks, and source or assemble reference datasets to measure progress.
    • Apply causal-inference principles to propose experiments that clarify biological mechanisms and validate model outputs.
    • Write high-quality, tested code and deploy models across multi-GPU or HPC environments.
    • Monitor model performance and iterate on improvements.
  • Research & Collaboration:
    • Stay current with advancements in machine learning and computational biology.
    • Prototype promising ideas and share findings with the team.
    • Mentor colleagues in best practices for data engineering, modeling, and experimental design.

Required Qualifications

  • PhD (or equivalent experience) in Machine Learning, Computational Biology, Bioinformatics, Computer Science, or a related field.
  • 3+ years of relevant experience.
  • Demonstrated expertise in applying deep learning to omics data at scale.
  • Proficiency in Python and modern deep-learning frameworks (e.g., PyTorch, JAX).
  • Experience designing and operating data pipelines for genomics, transcriptomics, proteomics, or metabolomics.
  • Solid understanding of causal inference, experimental design, and statistics.
  • Familiarity with software engineering best practices, including version control, code review, and continuous integration.

Preferred Qualifications

  • Experience working in cloud or HPC environments.
  • Experience with distributed training.
  • Familiarity with multimodal transformers.

About Iambic Therapeutics

Iambic is a clinical-stage life-science and technology company dedicated to developing novel medicines through its AI-driven discovery and development platform. Founded in 2020 and based in San Diego, Iambic has assembled a world-class team comprising pioneering AI experts and seasoned drug hunters. The Iambic platform has a proven track record of delivering new drug candidates to human clinical trials with exceptional speed, across various target classes and mechanisms of action. The company is advancing a pipeline of potentially best-in-class and first-in-class clinical assets, both internally and through partnerships, to address critical unmet patient needs.

Learn more about Iambic's team, platform, pipeline, and partnerships at iambic.ai.

Mission & Core Values

Iambic's mission is to deliver better medicines through innovations in AI-based discovery technologies. The company fosters a culture that is significantly enriched by the diversity of its people, encompassing differences in background, culture, national origin, religion, sexual orientation, and life experiences. Iambic is committed to building an inclusive environment where a diverse group of talented individuals collaborate to discover therapeutics and create groundbreaking technologies.

Pay and Benefits

Iambic Therapeutics offers a competitive compensation package, pension contributions, and flexible holiday allowances. Our UK office provides a modern and collaborative work environment situated in the heart of Bristol.

Skills

multi-omics data
genomics
transcriptomics
proteomics
metabolomics
data pipelines
benchmarking datasets
causal inference
deep learning
Python
PyTorch
JAX
computational biology
bioinformatics
HPC environments
experimental design

Axsome Therapeutics Inc

Develops therapies for CNS disorders

About Axsome Therapeutics Inc

Axsome Therapeutics develops therapies for central nervous system (CNS) disorders, focusing on conditions like major depressive disorder, treatment-resistant depression, and Alzheimer's agitation. Their main product, AXS-05, is an oral medication that works by blocking NMDA receptors in the brain, which helps regulate mood. This drug has shown positive results in clinical trials and has received special FDA status to speed up its approval process. Unlike many competitors, Axsome emphasizes addressing unmet medical needs in CNS disorders and aims to improve patient outcomes through rigorous research and development. The company's goal is to bring effective treatments to market, enhancing the quality of life for patients suffering from these conditions.

New York City, New YorkHeadquarters
2012Year Founded
$430.7MTotal Funding
IPOCompany Stage
Biotechnology, HealthcareIndustries
201-500Employees

Benefits

Performance Bonus
Company Equity

Risks

Increased competition from companies like Compass Pathways in the CNS market.
Potential delays in AXS-07 launch amid growing market anticipation.
Departure of key personnel like Lori Englebert may impact strategic direction.

Differentiation

Axsome focuses on CNS disorders with limited current treatment options.
AXS-05, an NMDA receptor antagonist, targets major depressive disorder and treatment-resistant depression.
Axsome's balanced portfolio includes both clinical and research stage products.

Upsides

FDA's fast-tracking of CNS treatments could expedite Axsome's drug approvals.
Increased investment in CNS R&D drives innovation, benefiting Axsome's pipeline.
Growing personalized medicine trend offers Axsome opportunities for tailored therapies.

Land your dream remote job 3x faster with AI